10 mg Tesamorelin (Research-Grade Peptide)

Growth Hormone-Releasing Hormone (GHRH) analogue — for laboratory research only

Product Overview

Tesamorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), designed for use in laboratory research. Each vial contains 10 mg of high-purity peptide, verified by Certificate of Analysis (COA). Supplied as lyophilized powder—store at –20 °C and reconstitute before use following lab best practices.

Research Highlights

• Reduces Visceral Fat: Clinical trials in HIV-associated lipodystrophy show significant VAT reduction and improved lipid profiles over 26 weeks. NEJM study
• Sustained 52-Week Results: –18% VAT maintained long-term, with triglyceride reduction and stable glucose metabolism. NATAP summary
• Improved Fat Quality: Increased VAT and SAT density observed in responders. PMC article
• Metabolic Improvements: LDL and non-HDL cholesterol reduced without glucose impairment in type 2 diabetes subjects. PLOS One study
• Cognitive Potential: Early data points to enhanced executive function and memory in older adults; more studies needed. Nature review

Product Details & Handling

• Form: Lyophilized powder, 10 mg vial
• Purity: ≥ 98% (COA provided)
• Storage: Keep at –20 °C, protect from light and moisture
• Handling: Use appropriate lab safety gear (PPE); refer to SDS for full instructions

Legal Disclaimer

This product is provided strictly for laboratory research use. It is not intended for human or veterinary consumption, therapeutic, diagnostic, or clinical application. Customers must comply with all applicable laws and institutional policies. Tesamorelin is not approved by the FDA for general use outside its specific prescription indication in HIV-associated lipodystrophy. Windy City Peptide does not provide medical advice or support for human use.